Clinical perspectives of PSMA PET/MRI for prostate cancer
Clinics
; 73(supl.1): e586s, 2018. graf
Article
em En
| LILACS
| ID: biblio-952840
Biblioteca responsável:
BR1.1
ABSTRACT
Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa.
Palavras-chave
Texto completo:
1
Base de dados:
LILACS
Assunto principal:
Neoplasias da Próstata
/
Imageamento por Ressonância Magnética
/
Glutamato Carboxipeptidase II
/
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada
/
Antígenos de Superfície
Limite:
Humans
/
Male
Idioma:
En
Revista:
Clinics
Assunto da revista:
MEDICINA
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Brasil